NeoGenomics

company

About

NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$200M
Industries
Biotechnology,Genetics,Health Care,Health Diagnostics,Medical,Pharmaceutical
Founded date
Oct 29, 1998
Number Of Employee
501 - 1000
Operating Status
Active
Stock Symbol
nasdaq:NEO
Legal Name
NeoGenomics Laboratories, Inc.

NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$385.10M
NeoGenomics has raised a total of $385.10M in funding over 2 rounds. Their latest funding was raised on May 5, 2021 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 5, 2021 Post-IPO Equity $200M 13 Detail
Dec 22, 2016 Post-IPO Debt $150M Detail
Mar 30, 2009 Post-IPO Equity $500K Detail
Nov 12, 1999 IPO $34.60M Detail

Investments

Number of Investments
Number of Lead Investments
3
1
NeoGenomics has made 3 investments. Their most recent investment was on Oct 14, 2022, when Fulcrum raised $18.80M.
Date Company Name
Round Money Raised Industry Lead Investor
Oct 14, 2022 Fulcrum
Series A $18.80M Enterprise Resource Planning (ERP)
Dec 9, 2020 Squire
Series C $45M Consumer
May 26, 2020 Inivata
Corporate Round $25M Biotechnology Yes

Employee Profiles

Number of Employee Profiles
17
NeoGenomics has 17 current employee profiles, including Executive George A. Cardoza

Exits

NeoGenomics has had 1 exits. NeoGenomics most notable exits include Inivata

Date Company Name Exit Type Industry
May 5, 2021 Inivata M&A Biotechnology Detail

Acquisition

NeoGenomics has acquired 5 organizations. Their most recent acquisition was Path Logic on Jul 8, 2014. They acquired Path Logic for $6M.

Date Company Name
Industry Acquisition Type Price
Jul 8, 2014 Path Logic
Biotechnology acquisition $ 6M Detail
Oct 21, 2015 Clarient
Biotechnology acquisition Detail
Oct 23, 2018 Genoptix
Communities acquisition Detail
Mar 24, 2021 Trapelo Health
Health Care acquisition $ 65M Detail
May 5, 2021 Inivata
Biotechnology acquisition Detail